WAVE LIFE SCIENCES LTD. Investment Income, Interest and Dividend
WAVE LIFE SCIENCES LTD. (WVE) reported Investment Income, Interest and Dividend of $10.48 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterestAndDividend · last filed 2026-02-26
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for the quarter ending 2024-12-31 was $3.74M, a 102.71% increase year-over-year.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for the quarter ending 2024-09-30 was $1.80M, a 8.27% decline year-over-year.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for the quarter ending 2024-06-30 was $2.09M, a 7.06% decline year-over-year.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for the quarter ending 2024-03-31 was $2.54M, a 35.34% increase year-over-year.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for fiscal 2025 was $10.48M, a 3.10% increase from fiscal 2024.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for fiscal 2024 was $10.16M, a 28.19% increase from fiscal 2023.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for fiscal 2023 was $7.93M, a 404.65% increase from fiscal 2022.
- WAVE LIFE SCIENCES LTD. investment income, interest and dividend for fiscal 2022 was $1.57M, a 5136.67% increase from fiscal 2021.
| Period end | Investment Income, Interest and Dividend 3 month | Investment Income, Interest and Dividend 6 month | Investment Income, Interest and Dividend 9 month | Investment Income, Interest and Dividend 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.48M 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.54M derived: sum of 2 quarters · filed 2026-02-26 | $7.63M derived: sum of 3 quarters · filed 2026-02-26 | $10.16M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.80M 10-Q · filed 2024-11-12 | $3.89M derived: sum of 2 quarters · filed 2024-11-12 | $6.42M 10-Q · filed 2024-11-12 | $8.27M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $2.09M 10-Q · filed 2024-08-08 | $4.63M 10-Q · filed 2024-08-08 | $6.47M derived: sum of 3 quarters · filed 2026-02-26 | $8.43M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $2.54M 10-Q · filed 2024-05-10 | $4.38M derived: sum of 2 quarters · filed 2026-02-26 | $6.34M derived: sum of 3 quarters · filed 2026-02-26 | $8.59M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.80M derived: sum of 2 quarters · filed 2026-02-26 | $6.05M derived: sum of 3 quarters · filed 2026-02-26 | $7.93M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.96M 10-Q · filed 2024-11-12 | $4.21M derived: sum of 2 quarters · filed 2024-11-12 | $6.08M 10-Q · filed 2024-11-12 | $6.91M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $2.25M 10-Q · filed 2024-08-08 | $4.12M 10-Q · filed 2024-08-08 | $4.95M derived: sum of 3 quarters · filed 2025-03-04 | $5.54M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $1.87M 10-Q · filed 2024-05-10 | $2.70M derived: sum of 2 quarters · filed 2025-03-04 | $3.29M derived: sum of 3 quarters · filed 2025-03-04 | $3.42M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $825.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.42M derived: sum of 2 quarters · filed 2025-03-04 | $1.54M derived: sum of 3 quarters · filed 2025-03-04 | $1.57M 10-K · filed 2025-03-04 |
| 2022-09-30 | $596.00K 10-Q · filed 2023-11-09 | $720.00K derived: sum of 2 quarters · filed 2023-11-09 | $746.00K 10-Q · filed 2023-11-09 | $751.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $124.00K 10-Q · filed 2023-08-03 | $150.00K 10-Q · filed 2023-08-03 | $155.00K derived: sum of 3 quarters · filed 2023-08-03 | $161.00K derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $26.00K 10-Q · filed 2023-05-03 | $31.00K derived: sum of 2 quarters · filed 2023-05-03 | $37.00K derived: sum of 3 quarters · filed 2023-05-03 | $45.00K derived: sum of 4 quarters · filed 2023-05-03 |
| 2021-12-31 | $5.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $11.00K derived: sum of 2 quarters · filed 2023-03-23 | $19.00K derived: sum of 3 quarters · filed 2023-03-23 | $30.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $6.00K 10-Q · filed 2022-11-10 | $14.00K derived: sum of 2 quarters · filed 2022-11-10 | $25.00K 10-Q · filed 2022-11-10 | $49.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $8.00K 10-Q · filed 2022-08-11 | $19.00K 10-Q · filed 2022-08-11 | $43.00K derived: sum of 3 quarters · filed 2022-08-11 | $66.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $11.00K 10-Q · filed 2022-05-12 | $35.00K derived: sum of 2 quarters · filed 2022-05-12 | $58.00K derived: sum of 3 quarters · filed 2022-05-12 | $191.00K derived: sum of 4 quarters · filed 2022-05-12 |
| 2020-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $47.00K derived: sum of 2 quarters · filed 2022-03-03 | $180.00K derived: sum of 3 quarters · filed 2022-03-03 | $568.00K 10-K · filed 2022-03-03 |
| 2020-09-30 | $23.00K 10-Q · filed 2021-11-10 | $156.00K derived: sum of 2 quarters · filed 2021-11-10 | $544.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $133.00K 10-Q · filed 2021-08-05 | $521.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | $388.00K 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |